Tyr809
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Phosphorylation Site Page:
Tyr809 - CSFR (human)

Site Information
DIMNDSNyIVKGNAR    SwissProt Entrez-Gene
Predicted information: Scansite
Orthologous residues: CSFR (mouse): Y807
Blast this site against: NCBI  SwissProt  PDB 
Available spectra:  2 CST

In vivo Characterization
Methods used to characterize site in vivo: mass spectrometry (1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14), mutation of modification site (15, 16, 17, 19, 20, 21), phospho-antibody (15, 16, 20), western blotting (15, 16, 17)
Disease tissue studied: breast cancer (7, 8, 11, 12, 13, 14), leukemia (5, 6), acute myelogenous leukemia (5, 6), lung cancer (2, 9, 10), non-small cell lung cancer (2, 9, 10)
Relevant cell line - cell type - tissue: 32D (myeloid) (15), 3T3 (fibroblast) (16, 17, 19), 3T3 (fibroblast) [SHP-2 (mouse), homozygous knockout] (20), FDCP-1 (myeloid) (21), GDM-1 (myeloid) (6), Jurkat (T lymphocyte) (3), lung (2, 9, 10), MCF-10A (breast cell) (1, 7, 8, 11, 12, 13, 14), MCF-10A (breast cell) [CSFR (human), transfection] (1), NCI-H2444 (pulmonary) (2), NKM-1 (myeloid) (5)

Controlled by
Regulatory protein: CSFR (human) (1)
Putative upstream kinases: CSFR (human) (15)
Kinases, in vitro: CSFR (human) (21)
Treatments: CSF-1 (15, 20), SU6656 (15)

Downstream Regulation
Effects of modification on CSFR: activity, induced (15, 21), phosphorylation (16)
Effects of modification on biological processes: cell cycle regulation (21), cell growth, altered (19), transcription, altered (16)


References

1

Knowlton ML, et al. (2010) Profiling Y561-Dependent and -Independent Substrates of CSF-1R in Epithelial Cells. PLoS One 5, e13587
21049007   Curated Info

2

Rikova K, et al. (2007) Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131, 1190-203
18083107   Curated Info

3

(2007) CST Curation Set: 3519; Year: 2007; SILAC: N; Biosample/Treatment: Jurkat(cell line)/pervanadate; Disease: T cell leukemia; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-pTyr Antibody Used to Purify Peptides prior to MS2: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

4

Schubert C, et al. (2007) Crystal structure of the tyrosine kinase domain of colony-stimulating factor-1 receptor (cFMS) in complex with two inhibitors. J Biol Chem 282, 4094-101
17132624   Curated Info

5

(2005) CST Curation Set: 818; Year: 2005; SILAC: N; Biosample/Treatment: NKM-1(cell line)/-; Disease: leukemia; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-pTyr Antibody Used to Purify Peptides prior to MS2: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

6

(2005) CST Curation Set: 893; Year: 2005; SILAC: N; Biosample/Treatment: GDM-1(cell line)/-; Disease: acute myelogenous leukemia; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-pTyr Antibody Used to Purify Peptides prior to MS2: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

7

(2005) CST Curation Set: 752; Year: 2005; SILAC: N; Biosample/Treatment: MCF-10A(cell line)/-; Disease: breast cancer; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-pTyr Antibody Used to Purify Peptides prior to MS2: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

8

(2005) CST Curation Set: 753; Year: 2005; SILAC: N; Biosample/Treatment: MCF-10A(cell line)/-; Disease: breast cancer; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-pTyr Antibody Used to Purify Peptides prior to MS2: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

9

(2005) CST Curation Set: 746; Year: 2005; SILAC: N; Biosample/Treatment: lung(tissue)/-; Disease: non-small cell lung cancer; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-pTyr Antibody Used to Purify Peptides prior to MS2: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

10

(2005) CST Curation Set: 692; Year: 2005; SILAC: N; Biosample/Treatment: lung(tissue)/-; Disease: non-small cell lung cancer; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-pTyr Antibody Used to Purify Peptides prior to MS2: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

11

(2005) CST Curation Set: 583; Year: 2005; SILAC: N; Biosample/Treatment: MCF-10A(cell line)/su 6656; Disease: breast cancer; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-pTyr Antibody Used to Purify Peptides prior to MS2: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

12

(2005) CST Curation Set: 584; Year: 2005; SILAC: N; Biosample/Treatment: MCF-10A(cell line)/-; Disease: breast cancer; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-pTyr Antibody Used to Purify Peptides prior to MS2: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

13

(2004) CST Curation Set: 498; Year: 2004; SILAC: N; Biosample/Treatment: MCF-10A(cell line)/-; Disease: breast cancer; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-pTyr Antibody Used to Purify Peptides prior to MS2: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

14

(2004) CST Curation Set: 499; Year: 2004; SILAC: N; Biosample/Treatment: MCF-10A(cell line)/-; Disease: breast cancer; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-pTyr Antibody Used to Purify Peptides prior to MS2: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

15

Rohde CM, Schrum J, Lee AW (2004) A juxtamembrane tyrosine in the colony stimulating factor-1 receptor regulates ligand-induced Src association, receptor kinase function, and down-regulation. J Biol Chem 279, 43448-61
15297464   Curated Info

16

Ezashi T, Roberts RM (2004) Regulation of interferon-tau (IFN-tau) gene promoters by growth factors that target the Ets-2 composite enhancer: a possible model for maternal control of IFN-tau production by the conceptus during early pregnancy. Endocrinology 145, 4452-60
15217985   Curated Info

17

Novak U, Nice E, Hamilton JA, Paradiso L (1996) Requirement for Y706 of the murine (or Y708 of the human) CSF-1 receptor for STAT1 activation in response to CSF-1. Oncogene 13, 2607-13
9000134   Curated Info

18

Joos H, et al. (1996) Tyrosine phosphorylation of the juxtamembrane domain of the v-Fms oncogene product is required for its association with a 55-kDa protein. J Biol Chem 271, 24476-81
8798707   Curated Info

19

Rabault B, Roussel MF, Quang CT, Ghysdael J (1996) Phosphorylation of Ets1 regulates the complementation of a CSF-1 receptor impaired in mitogenesis. Oncogene 13, 877-81
8761310   Curated Info

20

Novak U, et al. (1995) Colony-stimulating factor 1-induced STAT1 and STAT3 activation is accompanied by phosphorylation of Tyk2 in macrophages and Tyk2 and JAK1 in fibroblasts. Blood 86, 2948-56
7579387   Curated Info

21

Baker DA, Maher J, Roberts IA, Dibb NJ (1994) Evidence that ras and myc mediate the synergy between SCF or M-CSF and other haemopoietic growth factors. Leukemia 8, 1970-81
7526094   Curated Info

Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.